ProQR Therapeutics (NASDAQ:PRQR) Announces Quarterly Earnings Results, Hits Estimates

ProQR Therapeutics (NASDAQ:PRQR) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.10), Zacks reports. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%.

ProQR Therapeutics Price Performance

Shares of NASDAQ:PRQR opened at $1.85 on Thursday. ProQR Therapeutics has a 1-year low of $1.61 and a 1-year high of $4.62. The stock has a market cap of $151.11 million, a P/E ratio of -5.78 and a beta of 0.24. The firm has a fifty day moving average price of $2.29 and a 200 day moving average price of $2.62.

Analysts Set New Price Targets

A number of research analysts have recently commented on PRQR shares. Citigroup upgraded ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective on the stock in a report on Monday. JMP Securities reissued a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. Oppenheimer initiated coverage on shares of ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Finally, Chardan Capital reissued a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.17.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).